What coenzyme Q10 is

Coenzyme Q10 (INCI: ubiquinone, CAS 303-98-0) is a lipid-soluble benzoquinone: a quinone ring plus a long side chain of ten isoprene units — the "10" in Q10 refers to that chain length. It is not a foreign substance: it is already present in the inner mitochondrial membrane of human cells as a resident component of the respiratory chain, which is why it is widely used in cosmetics for an "antioxidant plus support your own defence" narrative.

Several grades are on the market: ubiquinone crystalline powder (yellow to orange), oil dispersions (commonly 10%–20% in a carrier such as caprylic/capric triglyceride), and more recently water-dispersible grades (nano-emulsified or liposome-encapsulated). The sourcing logic differs entirely between them: crystalline powder looks cheapest per kilogram but pushes dispersion and stability onto your lab; oil dispersions dose easily into the oil phase but carry a heavy vehicle load that is not cheap once converted to active content; water-dispersible grades solve aqueous application at the highest unit price, suiting serums and gels. Always verify the INCI name UBIQUINONE and the CAS number, and ask plainly whether the grade is ubiquinone or ubiquinol and at what active content — the oxidised and reduced forms are different raw materials with different pricing logic.

Three physico-chemical facts matter most: the melting range sits around 48–52 °C (so it undergoes a solid-to-liquid transition with temperature, which affects dosing), it is highly sensitive to light and oxygen (light and heat drive oxidative degradation, with colour shifting from yellow towards dark), and it is practically insoluble in water. Together these mean: it can go into an oil phase but not into any "nice-looking aqueous phase"; it can go on shelf but the pack must block light; and it can pass sampling but filling and storage temperatures must be written into the process file.

Ingredient fact box

How it works, plainly

Coenzyme Q10 works on three levels: an electron courier inside the cell, a chain-terminator in the lipid phase, and an antioxidant resource top-up at the topical level. The first two are its physiological day job; the third is what the formula must deliver — and the difficulty there has never been the mechanism, it has been delivery.

• Layer one: respiratory-chain electron carrier. In the inner mitochondrial membrane, coenzyme Q10 shuttles electrons between complexes I and II and complex III, a required step in oxidative phosphorylation and ATP production. That explains its endogenous status, but it is also the layer most over-read in marketing — "takes part in energy metabolism" does not mean "applying it recharges skin", and must never become "cell charging" or "boosts vitality".
• Layer two: lipid-phase antioxidant and regeneration. Its reduced form (ubiquinol) donates electrons to lipid peroxyl radicals, terminating the chain reaction, and reduces oxidised vitamin E back to its active form — a relay between the aqueous and lipid phases. This is the most defensible mechanistic basis for its use in anti-age formulas.
• Layer three: the practical conditions of topical use. Be clear here. Ubiquinone has a molecular weight of ≈863 Da and is lipophilic, so percutaneous penetration is inherently limited; how much actually reaches the skin depends on carrier design (oil-phase dissolution, nano-emulsification and liposomal encapsulation all change dispersion and deposition markedly), and the thin, small eye area is especially sensitive to deposition efficiency. So spend the budget on dispersion and delivery rather than on a higher use level.
• Where claims must stop. Write "helps improve the look of tiredness and dullness around the eyes", "supports the skin's own antioxidant defence", "raises the antioxidant reserve of the eye formula". Never "anti-fatigue", "treats dark circles", "delays ageing", "anti-inflammatory" or any medical or absolute claim.
• An honest note on evidence strength. Coenzyme Q10 has shown supportive results for skin antioxidant markers, lipid-peroxidation products and some ageing-appearance parameters in in-vitro and some human studies, but eye-area-specific controlled research is limited, and the carrier systems and use levels across studies are inconsistent, so conclusions should not be extrapolated directly. Verify on PubMed with "ubiquinone", "coenzyme Q10 skin" and "topical antioxidant", and stay cautious about single studies.

A blunt note for sourcing: coenzyme Q10 succeeds more easily in an eye cream than in a serum. A cream has an oil phase that genuinely dissolves it, whereas serums and gels require buying in solubilisation or nano-dispersion — often costing more than the active itself. If the positioning puts it as the lead antioxidant in eye care, develop it as a cream first; if it must go into a serum, buy a water-dispersible grade outright rather than trying to force plain ubiquinone with surfactants, because that formula tends to fail on 40 °C stability and long-term shelf life.

Which formats fit coenzyme Q10 best?

Use level and formulation notes (verify by bench trial)

Common reference level: a common reference range in eye care formulas is ≈0.05%–1%, with eye creams typically landing at 0.1%–0.5%. Because solubility in the oil phase is limited, piling on the level brings little benefit and invites precipitation, crystallisation and a tacky skin feel. The actual level is set on the bench by format, compatibility, target-market rules and stability data, converted against the assay on the supplier COA — a 10% or 20% oil dispersion must be dosed on active content.

• Light, heat and oxygen are the three red lines. Light-blocking packaging (opaque tube, airless bottle, pump) is not optional; add to the oil phase below 50 °C as a compromise between melt dispersion and thermal degradation, and use nitrogen or vacuum throughout; the formula must include an antioxidant (vitamin E, BHT type) as a sacrificial agent.
• Colour shift is an assay indicator. Ubiquinone is intrinsically yellow to orange, and a marked deepening of colour usually means oxidative degradation is under way. Put "visual colour comparison plus HPLC assay" into the stability release criteria rather than judging by whether the appearance is still "acceptable".
• The melting range drives dosing method. A solid-to-liquid transition at 48–52 °C means it may exist as crystals at lower temperature. Pre-melt, pre-dissolve into a stock solution, or use an oil dispersion to guarantee uniform distribution and avoid batch-to-batch assay drift.
• Aqueous systems must solve dispersion. For a water-based formula (serum, gel), do not force plain ubiquinone into solution with surfactants; buy a water-dispersible grade and verify particle size distribution, centrifugal stability and precipitation risk at 40 °C.
• Preservation still needs routine verification. Coenzyme Q10 is not a preservative. Systems with a higher oil proportion and lower water activity still require routine preservative efficacy testing.
• Raw-material spec must be explicit. State form (ubiquinone or ubiquinol), active content, carrier type, particle size for water-dispersible grades, heavy-metal and microbial limits, and require a COA plus stability data.
• Stability protocol. Run 40 °C for 3 months, freeze–thaw and a light-exposure test in parallel, with ubiquinone retention and colour change measured as release criteria; also watch precipitation and viscosity drift.

The figures above are common reference levels for eye care formulas; the actual use level is set by the formulation engineer based on dosage form, compatibility and target-market rules. Permitted use conditions, limits and labelling requirements differ by market — complete a compliance review for each destination before shipment. All descriptions here are general cosmetic applications and appearance or skin-feel statements, not medical advice or efficacy guarantees.

Compliance and market notes (verify per target market)

• China: first verify listing status and historical maximum use level in the Inventory of Existing Cosmetic Ingredients in China (2021 edition) (per the latest NMPA announcement), then complete filing under the Cosmetic Supervision and Administration Regulation. Where claims such as "anti-wrinkle", "firming" or "moisturising" appear in the efficacy-claim evaluation rules, the corresponding evaluation must be completed and its summary published. Note: "antioxidant" must map onto a claim category the rules actually list — do not upgrade it to an unlisted claim such as "anti-ageing".
• EU (EC) No 1223/2009: declare the ingredient and impurity profile accurately in the CPNP notification, PIF and CPSR, and complete the safety assessment; claims must meet the (EU) No 655/2013 common criteria. Ubiquinone is fairly widely used in EU cosmetics, but the safety assessment must still be done for the actual formula and use level.
• US MoCRA (2022): facility registration, product listing, safety substantiation, adverse-event reporting and record-keeping apply, with labelling under the FD&C Act and relevant 21 CFR provisions. Cosmetic ingredients and finished products generally do not undergo pre-market approval — never write "FDA approved".
• Claim red lines (all markets): never use medical or absolute wording such as "treats", "anti-inflammatory", "medical", "anti-fatigue", "delays ageing" or "repairs damaged skin". On the Chinese site use appearance and skin-feel wording such as "帮助改善眼周疲惫与暗沉外观", "Support皮肤自身的抗氧化防御" and "提升眼周配方抗氧化储备".
• Japan / Korea / Middle East: each follows its own cosmetic or quasi-drug pathway with different boundaries — verify per target market, and confirm listing status and label format before export.
• Recommended action: at project kick-off, give your regulatory adviser five items — ingredient, use level, dosage form, claim copy and packaging format — for one upfront review. Where a water-dispersible (nano or liposomal) grade is used, submit particle size and characterisation data as well, since some markets have separate notification expectations for nanomaterials.

Ingredient pairings

• Coenzyme Q10 + vitamin E (tocopherol) + squalane: the classic lipid-phase antioxidant trio. Vitamin E captures radicals at the interface, coenzyme Q10 regenerates it and sustains chain-termination capacity, and squalane supplies an inert oil-phase base. All three dissolve in the same oil phase, making this the simplest and highest-success-rate route.
• Coenzyme Q10 + acetyl hexapeptide-8 + panthenol: anti-age plus firming plus a soothing base. The peptide sits in the water phase and Q10 in the oil phase, so the formula needs a two-phase architecture with each carrying a different pathway.
• Coenzyme Q10 + ergothioneine + niacinamide: an aqueous-plus-lipid dual antioxidant network with even-tone support. Note that pairing ergothioneine with Q10 raises metal-ion chelation questions, so chelator levels must be controlled consistently across the formula.
• Coenzyme Q10 + ectoin + sodium hyaluronate: antioxidant protection plus barrier hydration, suited to long-term care for dry, sensitive eye areas. Ectoin sits in the water phase, so confirm the aqueous solubilisation route first.
• Coenzyme Q10 + retinoids: complementary antioxidant and anti-age pathways, but both are light- and oxygen-sensitive, so stability risk stacks. Lower each use level, strengthen the antioxidant system and light-blocking pack, and treat 40 °C plus light testing as a release precondition.
• Use with care: avoid combining with strongly oxidising ingredients (high-level peroxides); avoid high electrolyte loads that can break the dispersion; ship and store away from light and heat; and do not co-store it long-term with low-pH acids in the same aqueous phase.

Formulation pairing cards

FAQ

Image briefs